According to analysts, Sarepta Therapeutics’s stock has a predicted upside of 36.80% based on their 12-month price targets. What’s even more important is that Sarepta is demonstrating its ability to develop novel therapies for difficult-to-treat diseases. And its pipeline features other candidates that target this disease. Sarepta Therapeutics may not yet be profitable, but the company looks like a rising star in the biotech industry, and that’s one of the things that makes the company attractive.

• The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals.
• This particular call needed to be split into 9 different trades to become filled.
• This particular put needed to be split into 7 different trades to become filled.
• Lastly, Shopify should benefit from the trends in the e-commerce industry, which is still in high-growth mode.

The company’s shares closed last Wednesday at $6.29, close to its 52-week low of $4.69. Sarepta Therapeutics is a biotech company that focuses on developing medicines for rare diseases. The company has four approved products, all of which treat Duchenne muscular dystrophy (DMD) — a progressive genetic illness that leads to muscle degeneration and an extremely shortened lifespan. Sarepta Therapeutics’ portfolio of DMD therapies is generating consistently growing sales. In the second quarter, the company’s revenue rose by about 12% year over year to $261.2 million.

Premium Investing Services

Sarepta’s most recent therapy approval in June was its most important yet. The treatment in question is called Elevidys, the first gene therapy approved by the Food and Drug Administration to target the underlying causes of DMD. Elevidys is only indicated to treat patients ages 4 to 5 for now. The Route 79 program was created in 2018 to recognize exceptional individuals living with Duchenne as they pursue their post-secondary education. In 2022, Sarepta expanded the program to include siblings of individuals with Duchenne in recognition of the impact that a diagnosis of Duchenne may have on the entire family. Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement and personal essay.

Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Over the past year, e-commerce giant Shopify has made several important moves. After having held its prices steady for more than a decade, it increased them at the beginning of 2023.

Sarepta’s Gene Therapy Approval Lands With a Thud

15 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “moderate buy” SRPT shares. High-growth stocks tend to represent the technology, healthcare, and communications sectors.

It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta’s strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates.

The total cost received by the writing party (or parties) was $145.7K, with a price of $2470.0 per contract. There were 268 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. • Regarding MRNA MRNA, we observe a call option sweep with bullish sentiment. This particular call needed to be split into 9 different trades to become filled.

Sarepta Therapeutics (SRPT) Price Target & Analyst Ratings

It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development. • For DHR DHR, we notice a call option trade that happens to be bearish, expiring in 281 day(s) on June 21, 2024. This event was a transfer of 9 contract(s) at a $250.00 strike.

• Regarding MRK MRK, we observe a call option trade with neutral sentiment. The total cost received by the writing party (or parties) was $28.7K, with a price of $1150.0 per contract. There were 1090 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. • For ABBV ABBV, we notice a call option sweep that happens to be bearish, expiring in 491 day(s) on January 17, 2025. This event was a transfer of 75 contract(s) at a $180.00 strike. This particular call needed to be split into 12 different trades to become filled.

Most of Sarepta’s product candidates are at an early stage of development. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha’s Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service.

• Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.
• The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases.
• 15 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Sarepta Therapeutics in the last year.
• This particular call needed to be split into 3 different trades to become filled.

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. Wainwright maintained a Buy rating on Crinetics Pharmaceuticals, with a price target of $33.00. The company’s shares closed last Wednesday at $28.54, close to its 52-week high of $31.00. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases.

The higher fees Shopify now charges its merchants arguably reflect changing economic conditions. The tech giant also decided to exit its logistics business — a move that will boost its bottom line over the long run. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of SRPT stock can currently be purchased for approximately $118.98.

Health Care Stocks With Whale Alerts In Today’s Session

The other three approved DMD drugs are already doing well for it, but now it has another way to target this market. A second risk would then be the second label expansion I noted above, which is the targeting of non-ambulatory DMD patients in the ongoing ENVISION study. There is no assurance that Sarepta will be able to achieve positive results from this late-stage study. Thus, it may not be able to capture another chunk of the DMD market.

Again, the goal of this study is to target non-ambulatory DMD patients. However, this study targeting this specific DMD patient population is going to have a different endpoint. The primary endpoint for this study is going to be a change from baseline in total score of performance of upper limb version 2, which is going to be evaluated over a 72-week period.

At that point, management will either have to be patient or end up reducing the cost of this gene therapy. The global Duchenne Muscular Dystrophy drug market size is expected to reach $4.11 billion by 2023. Thus, one way to expand its label of ELEVIDYS would be to receive approval for all ambulatory DMD patients regardless of age. In order to accomplish this task, everything is resting on the ongoing pivotal EMBARK study. This late-stage study is expected to evaluate the use of ELEVIDYS for the treatment of 120 ambulatory boys with DMD who are between the ages of 4 to 7 years of age.

There were open contracts at this strike prior to today, and today 2012 contract(s) were bought and sold. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company how to calculate dividend per share in india is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases.

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

According to 18 analysts, the average rating for SRPT stock is “Strong Buy.” The 12-month stock price forecast is $180.0, which is an increase of 50.28% from the latest price. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals.

This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

The first risk to consider would be with respect to the upcoming results from the phase 3 EMBARK study, which is using ELEVIDYS for the treatment of ambulatory patients who are between ages 4 to 7. That’s because in order for the FDA to allow label expansion approval of ELEVIDYS for all ambulatory patients regardless of age, then it must meet the primary endpoint of it. There is no guarantee that this endpoint will be met, nor that the label expansion will occur. This might be possible with the ongoing EMBARK study, which is using ELEVIDYS to treat ambulatory DMD patients who are between 4 and 7 years of age. Investors won’t have to wait long to see results from this EMBARK study.

SRPT’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. This article was generated by Benzinga’s automated content engine and reviewed by an editor. Move your mouse over a quarter or year to see how estimates have changed over time.

The total cost received by the writing party (or parties) was $26.1K, with a price of $2910.0 per contract. There were 110 open contracts at this strike prior to today, and today 37 contract(s) were bought and sold. • For VEEV VEEV, we notice a put option trade that happens to be bullish, expiring in 1 day(s) https://1investing.in/ on September 15, 2023. This event was a transfer of 50 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $900.0 per contract. There were 3418 open contracts at this strike prior to today, and today 708 contract(s) were bought and sold.

Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals. Analysts like Sarepta Therapeutics more than other Medical companies. The consensus rating score for Sarepta Therapeutics is 2.93 while the average consensus rating score for medical companies is 2.65. The company has carved out a niche in the competitive e-commerce sector.

This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $25.1K, with a price of $2290.0 per contract. There were 264 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. • Regarding SRPT SRPT, we observe a put option sweep with bearish sentiment. This particular put needed to be split into 12 different trades to become filled.